Updates in Lung Cancer Screening: A Decade of Evidence

RECOMMENDED

Lung CancerFurther Publications

Physical activity and lung cancer screening (PALS): feasibility randomised controlled trial of exercise and physical activity in lung cancer screening

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Bonney A, Granger CL, Steinfort D, Patrick C, Marshall HM, Fong KM, Manser R

doi: 10.1186/s12931-025-03158-0

RECOMMENDED

Lung Cancer

Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir Rev

Hardavella G, Tavernaraki K, Lioumpas D, Boutsikou E, Karetsi E, Keramida E, Letsos A, Livanios K, Michailidou Ι, Benakis S, Pandi A, Papastavrou L, Stefanidis K, Zervas E, Agapitou T, Andritsou M, Anevlavis S, Apollonatos G, Apostolidou K, Bakiri K, Barmparessou Z, Bellou E, Bisirtzoglou D, Dagdilelis L, Fili E, Foroulis C, Gaitanakis S, Gkriniouk C, Kapetanakis G, Karagiannis K, Karampinis I, Kokkotou E, Kote A, Kostoulas A, Lambaki S, Magouliotis D, Mani M, Metaxas G, Miziou A, Mproupi K, Mytilinaiou S, Potaris K, Samitas K, Skouras V, Spyratos D, Stathoulopoulos A, Stasinopoulou M, Stournara L, Theodorakis E, Tsagaropoulos S, Vittorakis S, Zisis C, Zois P, Gkiozos I

doi: 10.1183/16000617.0249-2024

Lung Cancer

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Lung Cancer

Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S

doi: 10.1016/j.lungcan.2025.108840

Lung Cancer

Lung Cancer Screening Adherence in Centralized versus Decentralized Screening Programs A Meta-Analysis of U.S. Cohort Studies Among Individuals with Negative Baseline Results

Chest

Ezenwankwo E, Jones C, Nguyen DT, Eberth JM

doi: 10.1016/j.chest.2025.04.033

RECOMMENDED

Lung Cancer

Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T

doi: 10.1016/j.lungcan.2025.108671

Lung Cancer

Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets

Sci Rep

Seyringer S, Pilz MJ, Al-Naesan I, King MT, Bottomley A, Norman R, Schlosser L, Hell T, Gamper EM, EORTC Quality of Life Group

doi: 10.1038/s41598-024-83861-y

RECOMMENDED

Lung Cancer

A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Zerdes I, Kamali C, Johannsdottir B, Blasi M, Assmann C, Kazdal D, Stenzinger A, Skribek M, Ekman S, Christopoulos P, Tsakonas G

doi: 10.1016/j.lungcan.2024.108065

COMMENTED

Lung Cancer

Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Oncol

Vogel-Claussen J, Bollmann BA, May K, Stiebeler S, Dettmer S, Faron A, Kuhlmann A, Schmid-Bindert G, Kaaks R, Barkhausen J, Bohnet S, Reck M, HANSE investigators

doi: 10.1016/S1470-2045(25)00490-5

Lung Cancer

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)

Clin Lung Cancer

Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T

doi: 10.1016/j.cllc.2025.05.015

Related content

Physical activity and lung cancer screening (PALS): feasibility randomised controlled trial of exercise and physical activity in lung cancer screening

Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Lung Cancer Screening Adherence in Centralized versus Decentralized Screening Programs A Meta-Analysis of U.S. Cohort Studies Among Individuals with Negative Baseline Results

Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group

Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets

A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers

Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)